Conmed (NASDAQ: CNMD) reported Q2 EPS of $0.71, $0.09 better than the analyst estimate of $0.62. Revenue for the quarter came in at $255.2 million versus the consensus estimate of $248.31 million.

GUIDANCE:

Conmed sees FY2021 EPS of $3.15-$3.25, versus the consensus of $3.15. Conmed sees FY2021 revenue of $1.02-1.04 billion, versus the consensus of $1.02 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.